大多数接受阿特珠单抗-贝伐单抗 (AB) 治疗肝细胞癌的患者最终都会经历疾病进展。正在进行随机临床试验（RCT）以确定二线治疗。如果无法进行随机对照试验或患者不符合资格，通常会根据批准和报销政策开出索拉非尼处方。然而，支持这种方法的证据很少。 为了评估索拉非尼对永久停用 AB 的患者的疗效和安全性。ARTE 数据库前瞻性地收集在现实生活中接受 AB 治疗的患者。我们分析了接受索拉非尼作为二线治疗的患者的结果。在 213 名患者中，130 名 (61.0%) 永久停用 AB。其中 54 名患者接受了二线治疗，40 名患者接受了索拉非尼治疗。疾病控制率（DCR）为10.0%。中位无进展生存期 (PFS) 和总生存期分别为 3.3（95% 置信区间 [CI] 2.7-3.9）和 6.9 个月（95% CI 2.7-11.1）。 在 AB 进展的患者中，索拉非尼的疗效不同的结果是有限的。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

Most patients receiving atezolizumab-bevacizumab (AB) for hepatocellular carcinoma will eventually experience disease progression. Randomized clinical trials (RCTs) are undergoing to identify second-line treatments. Where RCTs are unavailable or patients are non-eligible, sorafenib is often prescribed based on approval and reimbursement policies. However, evidence supporting this approach is minimal.To assess the efficacy and safety of sorafenib in patients who permanently discontinued AB.The ARTE database prospectively collects patients treated with AB in a real-life setting. We analysed the outcome of patients who received sorafenib as second-line treatment.Amongst 213 patients, 130 (61.0 %) permanently discontinued AB. Of them, 54 received second- line treatments, and sorafenib was prescribed in 40 patients. The disease control rate (DCR) was 10.0 %. The median progression-free (PFS) and overall survival were 3.3 (95 % confidence interval [CI] 2.7-3.9) and 6.9 months (95 % CI 2.7-11.1), respectively.In patients progressing under AB, the efficacy of sorafenib on different outcomes is limited.Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.